Potential impact of a Moraxella catarrhalis vaccine in COPD.

Animals Antigens / immunology Bacterial Vaccines / immunology Disease Models, Animal Disease Susceptibility Health Impact Assessment Humans Moraxella catarrhalis / immunology Moraxellaceae Infections / complications Pulmonary Disease, Chronic Obstructive / epidemiology Vaccination
Airway pathogen COPD Chronic lung disease Moraxella catarrhalis Vaccine

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
03 09 2019
Historique:
received: 20 10 2016
accepted: 28 12 2016
pubmed: 12 2 2017
medline: 23 9 2020
entrez: 11 2 2017
Statut: ppublish

Résumé

Moraxella catarrhalis is the second most common cause of exacerbations in adults with COPD, resulting in enormous morbidity and mortality in this clinical setting. Vaccine development for M. catarrhalis has lagged behind the other two important causes of exacerbations in COPD, nontypeable Haemophilus influenzae and Streptococcus pneumoniae. While no licensed vaccine is currently available for M. catarrhalis, several promising candidate vaccine antigens have been identified and characterized and are close to entering clinical trials. Key steps that are required to advance vaccines for M. catarrhalis along the translational pipeline include standardization of assay systems to assess candidate antigens, identification of a reliable correlate of protection and expansion of partnerships between industry, academia and government to overcome regulatory hurdles. A vaccine to prevent M. catarrhalis infections in COPD would have a major impact in reducing morbidity, mortality and healthcare costs in COPD.

Identifiants

DOI: 10.1016/j.vaccine.2016.12.066 PMID: 28185742 PMC: PMC5545157
pubmed: 28185742
pii: S0264-410X(16)31300-7
doi: 10.1016/j.vaccine.2016.12.066
pmc: PMC5545157
mid: NIHMS840200
pii:
doi:

Substances chimiques

Antigens 0
Bacterial Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5551-5558

Subventions

Organisme : NIDCD NIH HHS
ID : F32 DC015393
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI019641
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC012200
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001412
Pays : United States

Informations de copyright

Copyright © 2016 Elsevier Ltd. All rights reserved.

Références

Infect Immun. 1999 Mar;67(3):1310-6
pubmed: 10024576
J Infect Dis. 1999 Jul;180(1):133-40
pubmed: 10353871
Infect Immun. 1999 Sep;67(9):4578-85
pubmed: 10456903
J Bacteriol. 2000 Mar;182(5):1364-73
pubmed: 10671460
N Engl J Med. 2000 Jul 27;343(4):269-80
pubmed: 10911010
Int Microbiol. 1999 Sep;2(3):137-44
pubmed: 10943406
Infect Immun. 2000 Nov;68(11):6250-6
pubmed: 11035732
Vaccine. 2000 Dec 8;19 Suppl 1:S101-7
pubmed: 11163472
Infect Immun. 2001 Jun;69(6):3576-80
pubmed: 11349016
J Immunol. 2001 Aug 15;167(4):2112-20
pubmed: 11489995
Am J Respir Crit Care Med. 2001 Aug 1;164(3):358-64
pubmed: 11500333
N Engl J Med. 2002 Aug 15;347(7):465-71
pubmed: 12181400
Thorax. 2002 Oct;57(10):847-52
pubmed: 12324669
J Antimicrob Chemother. 2002 Dec;50 Suppl S2:59-73
pubmed: 12556435
Infect Immun. 2003 Mar;71(3):1288-94
pubmed: 12595444
Infect Immun. 2003 Aug;71(8):4341-50
pubmed: 12874311
Chest. 2003 Aug;124(2):459-67
pubmed: 12907529
Lancet. 1953 Sep 12;265(6785):534-7
pubmed: 13097990
FEMS Immunol Med Microbiol. 2004 Jun 1;41(2):109-15
pubmed: 15145454
Eur Respir J. 2004 May;23(5):698-702
pubmed: 15176682
Vaccine. 2004 Jun 30;22(20):2533-40
pubmed: 15193378
J Infect Dis. 2004 Jul 15;190(2):352-5
pubmed: 15216472
Vaccine. 2004 Sep 3;22(25-26):3449-56
pubmed: 15308371
J Infect Dis. 1992 Apr;165(4):644-50
pubmed: 1532405
Am J Respir Crit Care Med. 2005 Jul 15;172(2):195-9
pubmed: 15805178
Infect Immun. 2005 May;73(5):2790-6
pubmed: 15845482
Pharmacoeconomics. 2005;23(4):345-63
pubmed: 15853435
J Virol. 2005 May;79(10):6035-42
pubmed: 15857989
Infect Immun. 2005 Jun;73(6):3471-8
pubmed: 15908376
Infect Immun. 2005 Aug;73(8):5127-36
pubmed: 16041029
Thorax. 2005 Nov;60(11):925-31
pubmed: 16055622
J Bacteriol. 2005 Sep;187(18):6528-35
pubmed: 16159786
JAMA. 2005 Sep 14;294(10):1255-9
pubmed: 16160134
Infect Immun. 2005 Oct;73(10):6601-7
pubmed: 16177336
Infect Immun. 2005 Dec;73(12):8161-6
pubmed: 16299311
FEMS Immunol Med Microbiol. 2006 Feb;46(1):139-46
pubmed: 16420607
Vaccine. 2006 May 29;24(22):4804-11
pubmed: 16616975
JAMA. 2006 Jul 12;296(2):202-11
pubmed: 16835426
Chest. 2006 Jul;130(1):133-42
pubmed: 16840393
J Infect Dis. 2006 Aug 15;194(4):493-7
pubmed: 16845633
J Bacteriol. 2006 Nov;188(22):7840-52
pubmed: 16963572
Acta Biochim Pol. 2006;53(3):445-56
pubmed: 16964325
J Bacteriol. 2007 Jan;189(1):76-82
pubmed: 17041038
Infect Immun. 2007 Jan;75(1):314-24
pubmed: 17088358
Infect Immun. 2007 Apr;75(4):1778-84
pubmed: 17101651
FEMS Microbiol Lett. 2007 Feb;267(2):207-13
pubmed: 17166229
Infect Immun. 2007 Jun;75(6):2974-80
pubmed: 17371852
Infect Immun. 2007 Jun;75(6):2818-25
pubmed: 17403868
Infect Immun. 2007 Jun;75(6):2929-36
pubmed: 17420235
J Infect Dis. 2007 Jun 1;195(11):1661-70
pubmed: 17471436
Vaccine. 2007 Jun 15;25(25):4801-8
pubmed: 17507119
Eur Respir J. 2007 Jun;29(6):1224-38
pubmed: 17540785
Infect Immun. 2007 Dec;75(12):5559-64
pubmed: 17908808
Am J Respir Crit Care Med. 2008 Apr 15;177(8):853-60
pubmed: 18202344
Infect Immun. 2008 Apr;76(4):1599-607
pubmed: 18227159
Clin Infect Dis. 2008 Mar 1;46(5):726-31
pubmed: 18230042
J Bacteriol. 2008 Dec;190(24):7994-8002
pubmed: 18931134
N Engl J Med. 2008 Nov 27;359(22):2355-65
pubmed: 19038881
Clin Vaccine Immunol. 2009 May;16(5):653-9
pubmed: 19321697
Clin Infect Dis. 2009 Jul 1;49(1):124-31
pubmed: 19480579
Cell Microbiol. 2009 Sep;11(9):1399-408
pubmed: 19500108
Vaccine. 2009 Nov 23;27(50):7065-72
pubmed: 19786139
Mol Microbiol. 2010 Mar;75(6):1426-44
pubmed: 20199596
FEMS Microbiol Rev. 2011 Jan;35(1):124-46
pubmed: 20584083
MBio. 2010 Jul 06;1(3):null
pubmed: 20802829
Infect Immun. 2011 Feb;79(2):846-57
pubmed: 21134967
Int J Chron Obstruct Pulmon Dis. 2010 Dec 09;5:435-44
pubmed: 21191438
Gene. 2011 May 15;477(1-2):19-23
pubmed: 21256201
Vaccine. 2011 Jun 6;29(25):4210-7
pubmed: 21501641
Antimicrob Agents Chemother. 2011 Aug;55(8):3845-53
pubmed: 21576428
Glycoconj J. 2011 May;28(3-4):165-82
pubmed: 21590368
Vaccine. 2011 Aug 5;29(34):5603-10
pubmed: 21704103
J Clin Invest. 2011 Sep;121(9):3657-65
pubmed: 21841308
J Med Virol. 2011 Nov;83(11):2008-17
pubmed: 21915878
Mol Microbiol. 2011 Nov;82(4):836-50
pubmed: 21923771
PLoS One. 2011;6(12):e29553
pubmed: 22216312
Lancet. 2012 Apr 7;379(9823):1341-51
pubmed: 22314182
Front Immunol. 2011 May 16;2:13
pubmed: 22566804
PLoS One. 2012;7(6):e40088
pubmed: 22768228
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
J Infect. 2013 Mar;66(3):247-54
pubmed: 23266462
Microbes Infect. 2013 May;15(5):375-87
pubmed: 23474333
Ann Otol Rhinol Laryngol. 2013 Feb;122(2):109-13
pubmed: 23534125
Respirology. 2013 Aug;18(6):996-1002
pubmed: 23600594
J Infect Chemother. 2013 Jun;19(3):412-25
pubmed: 23657429
PLoS One. 2013 May 09;8(5):e64422
pubmed: 23671716
PLoS One. 2013 Jul 02;8(7):e67881
pubmed: 23844117
Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56
pubmed: 23898922
J Infect. 2013 Dec;67(6):516-23
pubmed: 24055804
Pathog Dis. 2014 Apr;70(3):280-8
pubmed: 24391058
Eur Respir J. 2014 Jul;44(1):87-96
pubmed: 24627537
J Infect Dis. 2014 Oct 15;210(8):1306-10
pubmed: 24771863
Acta Otolaryngol. 2014 Jul;134(7):684-90
pubmed: 24834935
Infect Immun. 2014 Aug;82(8):3503-12
pubmed: 24914218
Cell Host Microbe. 2014 Jul 9;16(1):55-67
pubmed: 25011108
Chest. 2015 Jan;147(1):46-55
pubmed: 25103335
Infect Immun. 2014 Nov;82(11):4802-12
pubmed: 25156728
Infect Immun. 2014 Nov;82(11):4758-66
pubmed: 25156736
Respir Res. 2014 Sep 14;15:114
pubmed: 25218165
Pathog Dis. 2015 Mar;73(2):1-8
pubmed: 25251686
Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27
pubmed: 25830527
J Infect Dis. 1989 Dec;160(6):999-1004
pubmed: 2584766
Pediatr Infect Dis J. 2015 Jul;34(7):753-60
pubmed: 25923426
Pathog Dis. 2015 Jul;73(5):null
pubmed: 26014114
Infect Immun. 2015 Sep;83(9):3497-505
pubmed: 26099587
Infect Immun. 2015 Sep;83(9):3458-69
pubmed: 26099590
J Infect. 2015 Oct;71(4):458-69
pubmed: 26149186
Pediatr Infect Dis J. 2015 Oct;34(10):1056-62
pubmed: 26164848
Vaccine. 2015 Oct 26;33(43):5809-5814
pubmed: 26392013
Am J Respir Crit Care Med. 2015 Nov 1;192(9):1036-44
pubmed: 26517417
Infect Immun. 2015 Nov 23;84(2):432-8
pubmed: 26597985
Vaccine. 2016 Jan 20;34(4):531-539
pubmed: 26667610
J Infect Dis. 2016 Jun 15;213(12):1938-45
pubmed: 26908723
FASEB J. 2016 Jun;30(6):2426-34
pubmed: 26979086
Pediatrics. 2016 Apr;137(4):
pubmed: 27020793
Methods Mol Biol. 2016;1403:445-69
pubmed: 27076147
Vaccine. 2016 Jul 19;34(33):3855-61
pubmed: 27265455
PLoS One. 2016 Jul 08;11(7):e0158689
pubmed: 27391026
J Pediatr. 1980 Sep;97(3):364-9
pubmed: 6967963
Mol Microbiol. 1993 Oct;10(1):87-97
pubmed: 7968522
Microb Pathog. 1995 Oct;19(4):215-25
pubmed: 8825909
J Infect Dis. 1998 Dec;178(6):1667-75
pubmed: 9815219

Auteurs

Antonia C Perez (AC)

Clinical and Translational Research Center, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA; Division of Infectious Diseases, Department of Medicine, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA.

Timothy F Murphy (TF)

Clinical and Translational Research Center, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA; Division of Infectious Diseases, Department of Medicine, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA; Department of Microbiology, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA. Electronic address: murphyt@buffalo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antibactériens › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Prédisposition aux maladies › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Organisations et économie des soins de santé › Évaluation des impacts sur la santé › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Moraxellaceae › Moraxella › Moraxella (Branhamella) catarrhalis › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram négatif › Infections à Moraxellaceae › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › Potential impact of a Moraxella catarrhalis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Potential impact of a Moraxella catarrhalis...